LifeMD: Selling WorkSimpli Could Be A Catalyst [Seeking Alpha]
LifeMD, Inc. (LFMD)
Company Research
Source: Seeking Alpha
Summary LifeMD's Q2 2024 earnings were mixed, with management failing to monetize the non-core WorkSimpli asset, leading me to assign it no value. Despite management's over-promising, LifeMD's telehealth and GLP1 offerings show significant potential, with the stock priced at 14x forward EBITDA. I have revised my price target from $20 to $15 per share by summer 2025, due to management's credibility issues and uncertainties in GLP1 prospects. LifeMD remains a compelling investment with strong fundamentals and a solid balance sheet, but it's a high-risk, high-return opportunity. Ljupco/iStock via Getty Images Investment Thesis LifeMD, Inc. NASDAQ: LFMD ) reported a mixed Q2 2024 earnings result and guidance. Management states that its non-core asset, WorkSimpli, had some mishaps in Q2, but these aspects are now behind themselves. And yet, this was the same narrative that they provided last quarter. Consequently, I now believe that WorkSimpli has no value . Or better put,
Show less
Read more
Impact Snapshot
Event Time:
LFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LFMD alerts
High impacting LifeMD, Inc. news events
Weekly update
A roundup of the hottest topics
LFMD
News
- LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred StockGlobeNewswire
- LifeMD, Inc. (NASDAQ: LFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $15.00 price target on the stock.MarketBeat
- LifeMD Announces Major Enhancements to its Weight Management Program, Expanding Patient Access to Branded GLP-1 Therapies and Introducing New Treatment OptionsGlobeNewswire
- LifeMD to Participate in Three Investor Conferences During SeptemberGlobeNewswire
- LifeMD, Inc. (NASDAQ: LFMD) is now covered by analysts at B. Riley. They set a "buy" rating and a $11.00 price target on the stock.MarketBeat
LFMD
Earnings
- 8/7/24 - Beat
LFMD
Sec Filings
- 9/12/24 - Form 4
- 8/20/24 - Form 4
- 8/13/24 - Form 424B3
- LFMD's page on the SEC website